Nicox S.A. (OTCMKTS:NICXF – Free Report) – HC Wainwright dropped their Q4 2024 earnings per share (EPS) estimates for Nicox in a note issued to investors on Tuesday, April 23rd. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.06) per share for the quarter, down from their prior forecast of ($0.05). The consensus estimate for Nicox’s current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Nicox’s Q1 2024 earnings at ($0.03) EPS, Q2 2024 earnings at ($0.09) EPS, Q3 2024 earnings at ($0.07) EPS and FY2024 earnings at ($0.26) EPS.
Nicox Stock Performance
NICXF stock remained flat at $0.44 during midday trading on Thursday. The stock’s 50 day simple moving average is $0.44 and its 200-day simple moving average is $0.52. Nicox has a twelve month low of $0.44 and a twelve month high of $0.44.
About Nicox
Nicox SA operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial.
Featured Articles
- Five stocks we like better than Nicox
- ESG Stocks, What Investors Should Know
- Hasbro’s Management Made All the Right Calls This Quarter
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Nicox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nicox and related companies with MarketBeat.com's FREE daily email newsletter.
